DE60023139D1 - Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen - Google Patents

Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen

Info

Publication number
DE60023139D1
DE60023139D1 DE60023139T DE60023139T DE60023139D1 DE 60023139 D1 DE60023139 D1 DE 60023139D1 DE 60023139 T DE60023139 T DE 60023139T DE 60023139 T DE60023139 T DE 60023139T DE 60023139 D1 DE60023139 D1 DE 60023139D1
Authority
DE
Germany
Prior art keywords
treatment
diseases
il6ril6
neurodeegenerative
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023139T
Other languages
English (en)
Other versions
DE60023139T2 (de
Inventor
Michel Revel
Judith Chebath
Marina Pizzi
Pierfranco Spano
Ursula Boschert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Applied Research Systems ARS Holding NV filed Critical Yeda Research and Development Co Ltd
Publication of DE60023139D1 publication Critical patent/DE60023139D1/de
Application granted granted Critical
Publication of DE60023139T2 publication Critical patent/DE60023139T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60023139T 1999-06-21 2000-06-21 Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen Expired - Lifetime DE60023139T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13058699A IL130586A0 (en) 1999-06-21 1999-06-21 IL6RIL6 chimera for the treatment of demyelinating diseases
IL13058699 1999-06-21
PCT/IL2000/000363 WO2000078331A2 (en) 1999-06-21 2000-06-21 Il6ril6 chimera for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
DE60023139D1 true DE60023139D1 (de) 2006-02-23
DE60023139T2 DE60023139T2 (de) 2006-05-04

Family

ID=11072949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023139T Expired - Lifetime DE60023139T2 (de) 1999-06-21 2000-06-21 Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen

Country Status (21)

Country Link
US (1) US7201896B1 (de)
EP (1) EP1185293B1 (de)
JP (1) JP4846148B2 (de)
KR (1) KR100678290B1 (de)
CN (1) CN1164328C (de)
AT (1) ATE306280T1 (de)
AU (1) AU778662B2 (de)
BR (1) BR0011363A (de)
CA (1) CA2374997C (de)
DE (1) DE60023139T2 (de)
DK (1) DK1185293T3 (de)
EA (1) EA004626B1 (de)
EE (1) EE05559B1 (de)
ES (1) ES2250140T3 (de)
HK (1) HK1047549A1 (de)
IL (2) IL130586A0 (de)
MX (1) MXPA02000116A (de)
NO (1) NO329028B1 (de)
UA (1) UA76695C2 (de)
WO (1) WO2000078331A2 (de)
ZA (1) ZA200109488B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030364B2 (ja) 2000-09-14 2012-09-19 アレス トレーディング ソシエテ アノニム ハンチントン病におけるｉｌ−６ｒ／ｉｌ−６キメラの使用
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
CA2443777A1 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1631662A1 (de) 2003-06-12 2006-03-08 Yeda Research & Development Company, Ltd. Verbesserung der differenzierung von oligodendrozyten
WO2005047492A1 (en) * 2003-11-14 2005-05-26 Olsson Mats J Melanocytes in therapy of neurodegenerative diseases
IL161672A0 (en) * 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CA3014340A1 (en) * 2016-02-12 2017-08-17 Als Therapy Development Institute Measurement of als progression based on kinetic data
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JPH1148413A (ja) 1997-08-06 1999-02-23 Dainippon Printing Co Ltd ホルムアルデヒド捕捉壁紙およびその製造方法
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤

Also Published As

Publication number Publication date
KR100678290B1 (ko) 2007-02-05
EP1185293A2 (de) 2002-03-13
EP1185293B1 (de) 2005-10-12
MXPA02000116A (es) 2003-07-21
ZA200109488B (en) 2002-11-18
EA200200063A1 (ru) 2002-06-27
ES2250140T3 (es) 2006-04-16
DK1185293T3 (da) 2005-12-27
BR0011363A (pt) 2002-02-26
WO2000078331A3 (en) 2001-07-05
ATE306280T1 (de) 2005-10-15
CA2374997C (en) 2010-04-13
EE05559B1 (et) 2012-08-15
EA004626B1 (ru) 2004-06-24
JP4846148B2 (ja) 2011-12-28
CN1164328C (zh) 2004-09-01
DE60023139T2 (de) 2006-05-04
EE200100689A (et) 2003-02-17
US7201896B1 (en) 2007-04-10
NO20015673D0 (no) 2001-11-20
UA76695C2 (uk) 2006-09-15
IL147188A (en) 2015-09-24
NO329028B1 (no) 2010-08-02
CA2374997A1 (en) 2000-12-28
AU778662B2 (en) 2004-12-16
CN1364088A (zh) 2002-08-14
AU5423100A (en) 2001-01-09
WO2000078331A2 (en) 2000-12-28
IL130586A0 (en) 2000-06-01
KR20020013901A (ko) 2002-02-21
JP2003502382A (ja) 2003-01-21
HK1047549A1 (en) 2003-02-28
NO20015673L (no) 2001-12-17

Similar Documents

Publication Publication Date Title
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
RS20060023A (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
DE60102471D1 (de) Indolderivate zur verwendung in der behandlung von zns-störungen
DE60017136D1 (de) Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat
ATE381324T1 (de) Verwendung von mecamylamine zur behandlung von neuropsychiatrischen krankheiten die auf nicotin ansprechen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH

Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD., REHOV, IL